ClinicalTrials.gg
Enrolling by invitationNCT07943234Updated Nov 17, 2026

Corneal Endothelium in Active Thyroid Eye Disease Treated With Local Steroid Injection

An observational study in Thyroid Eye Disease, TED, sponsored by Assiut University. Enrolling by invitation at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Assiut University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
38
Ages
18 Years and older
Sex
All
01

Study summary

TED is an autoimmune disease that may cause stress to the corneal endothelium which may differ by the degree of inflammation.

Previous studies found that corneal endothelial cell morphology significantly changed in active TED patients compared with inactive TED patients.

The mechanism underlying the morphological changes in corneal endothelium of active TED is still unclear. One possible explanation is increased ocular surface inflammation, particularly during the active phase. Huang et al. reported elevated levels of tear inflammatory cytokines, including interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor (TNF)-α in active TED compared to inactive TED and controls. Villani et al. demonstrated a higher number of activated corneal keratocytes in active TED, indicating more pronounced corneal inflammation.

Local injection of steroid has been utilized in active TED with promising results. the local steroid injection has the advantage of delivering the steroid directly to the site of the pathology maximizing its concentration and effect and minimizing the systemic side effects of steroid.

All Previous reports about corneal endothelial changes in TED were of cross-sectional design and lacks longitudinal follow-up. To the best of authors, knowledge, this is the first study to evaluate changes in corneal endothelial morphology in active TED patients following local steroid treatment.

Read the detailed description

Thyroid eye disease (TED) is an autoimmune orbital disorder commonly associated with autoimmune thyroid dysfunction. The disease predominantly affects the extraocular muscles and orbital adipose tissue. Although inflammatory activity typically subsides within 12-18 months, the residual structural changes may persist and adversely affect visual performance, appearance, quality of life, and socioeconomic functioning.

The clinical course of TED, originally characterized by Rundle, follows an initial active inflammatory stage and a subsequent inactive phase. During the active stage, immune-cell infiltration, cytokine-mediated inflammation, fibroblast activation, and tissue edema contribute to orbital tissue remodeling. As inflammation gradually resolves, the disease enters a stable phase; however, the development of fibrosis may lead to permanent tissue changes and can necessitate rehabilitative surgical management.

Corneal endothelium has been found to be changed in systemic diseases. TED is an autoimmune disease that may cause corneal endothelial stress which may differ by the degree of inflammation.

Previous studies found that corneal endothelial cell morphology significantly changed in active phase of TED patients .

This prospective longitudinal observational study aims to to evaluate changes in corneal endothelial morphology in thyroid eye disease patients following management by local betamethasone injection using specular microscopy.

02

Conditions studied

  • Thyroid Eye Disease, TED

Browse trials for

03

In context

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

This study's planned enrollment of 38 is below the median of 80 across 45 observational studies indexed under Graves Ophthalmopathy.

Browse Graves Ophthalmopathy studies →

Lead sponsor

Assiut University is the lead sponsor of 5,088 studies on the registry; 2,185 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Active thyroid eye disease patients who will receive local steroid treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of thyroid eye disease
  • patients above age of 18
  • TED duration less than 18 months\& clinical activity score equal or more than 3

Exclusion criteria

Exclusion Criteria:

  • 1. History of ocular trauma or surgery. 2. Topical ocular medication use, previous ophthalmic intervention, contact lens wear 3. Ophthalmic diseases, such as corneal disease, glaucoma, or any ocular disease that might affect the corneal endothelium 4. uncontrolled hypertension, diabetes mellitus, or systemic diseases other than thyroid condition which may have an impact on the corneal endothelium 5. Patients in the fibrotic phase of thyroid eye disease. 6. to therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
38 participants (estimated)
Patient registry
No

Groups and cohorts

  • TED

    active TED

06

What researchers measure

Primary outcomes

  1. Coefficient of Variation (CV) & Hexagonality (HEX) as percentage

    A statistical measure of the variation in individual cell size and normal hexagonal shape. These parameters will be assessed in active thyroid eye disease patients before and after local betamethasone injection using specular microscopy (NIDEK CEM 530)

    Time frame: before injection ( baseline measures) and 1 month post injection measures after local steroid injection

Secondary outcomes

  1. Endothelial Cell Density (ECD)

    The number of endothelial cells per square millimeter (cells/mm²)

    Time frame: before injection ( baseline measures) and 1 month post injection measures after local steroid injection

  2. Average Cell Area (AVG)

    The mean surface area of an individual endothelial cell (measured in μm²).

    Time frame: before injection ( baseline measures) and 1 month post injection measures after local steroid injection

  3. Central Corneal Thickness (CCT)

    The thickness of the cornea at its center

    Time frame: before injection ( baseline measures) and 1 month post injection measures after local steroid injection

07

Study locations

1 site
  • Assiut University
    Asyut, Egypt
08

References and documents

Publications

  • Uzlu D, Bulanik FT, Erdol H, Gunay M, Bulanik OB. An evaluation of corneal endothelial cell morphology in patients with thyroid-associated ophthalmopathy. Int Ophthalmol. 2023 Aug;43(8):2867-2873. doi: 10.1007/s10792-023-02690-6. Epub 2023 Mar 27. PubMed 36971926 ↗
  • Oklar M, Yazicioglu T, Ozen MC, Agackesen A, Gun RD, Tezcan KA. Evaluation of corneal endothelium and correlation with disease severity in patients with Graves' ophthalmopathy: A specular microscopy-based study. Photodiagnosis Photodyn Ther. 2023 Jun;42:103592. doi: 10.1016/j.pdpdt.2023.103592. Epub 2023 May 3. PubMed 37146893 ↗
  • Zhou M, Wu D, Yu F, Hong S, Ye J, Wang C, Li Y, Du M, Xiao H, Wan P. Corneal Endothelium: A Promising Quantitative Index for Graves Ophthalmopathy Activity Evaluation. Am J Ophthalmol. 2021 Oct;230:216-223. doi: 10.1016/j.ajo.2021.05.020. Epub 2021 Jun 6. PubMed 34102155 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.

Of 20 observational studies under Graves Ophthalmopathy, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 59. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 17, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Mar 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943234
Lead sponsor
Assiut University
Responsible party
Rawda Abdelnasser Awad (Dr, Assiut University) — Principal investigator
First posted
Nov 17, 2026
Start date
Mar 1, 2026
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 17, 2026
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion